Drug intelligence / Profile preview

AB-201 + cyclophosphamide + fludarabine

Development stage: Unknown
Lead developer: Artiva Biotherapeutics
Modality: Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**AB-201 + cyclophosphamide + fludarabine** is an investigational multi-drug regimen used in clinical trials for patients with advanced HER2-positive solid tumors, such as breast and gastric/gastroesophageal junction cancers. AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy developed for outpatient treatment of solid tumors. Cyclophosphamide and fludarabine are chemotherapeutic agents used as lymphodepleting preparatory agents to facilitate adoptive cell therapy by decreasing host immune response and increasing engraftment and efficacy of the infused cell product.

Other names: AB-201 + cyclophosphamide + fludarabine

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on AB-201 + cyclophosphamide + fludarabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB-201 + cyclophosphamide + fludarabine.

Explore the full profile